Guyasuta Investment Advisors Inc. Sells 2,225 Shares of Johnson & Johnson (NYSE:JNJ)

Guyasuta Investment Advisors Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 262,893 shares of the company’s stock after selling 2,225 shares during the period. Johnson & Johnson comprises approximately 3.0% of Guyasuta Investment Advisors Inc.’s investment portfolio, making the stock its 9th biggest position. Guyasuta Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $41,206,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Massachusetts Wealth Management raised its position in shares of Johnson & Johnson by 4.2% in the third quarter. Massachusetts Wealth Management now owns 16,105 shares of the company’s stock valued at $2,508,000 after buying an additional 650 shares during the last quarter. Apeiron RIA LLC raised its holdings in Johnson & Johnson by 4.0% in the 3rd quarter. Apeiron RIA LLC now owns 3,800 shares of the company’s stock valued at $592,000 after acquiring an additional 145 shares during the last quarter. Chronos Wealth Management LLC lifted its stake in Johnson & Johnson by 1.5% in the 3rd quarter. Chronos Wealth Management LLC now owns 34,963 shares of the company’s stock worth $5,445,000 after purchasing an additional 506 shares in the last quarter. Connecticut Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 46.6% during the 3rd quarter. Connecticut Wealth Management LLC now owns 18,320 shares of the company’s stock worth $2,853,000 after purchasing an additional 5,825 shares during the last quarter. Finally, TFG Advisers LLC grew its holdings in Johnson & Johnson by 0.4% in the 3rd quarter. TFG Advisers LLC now owns 18,330 shares of the company’s stock valued at $2,855,000 after buying an additional 67 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.4 %

JNJ opened at $149.27 on Friday. The business has a fifty day moving average price of $154.44 and a 200 day moving average price of $155.08. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.91. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The stock has a market capitalization of $359.23 billion, a price-to-earnings ratio of 9.31, a PEG ratio of 2.47 and a beta of 0.55.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.68 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.32%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s payout ratio is 29.68%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on JNJ. Royal Bank of Canada decreased their price objective on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 17th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, April 15th. Finally, Bank of America lowered their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $175.86.

Insider Buying and Selling

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.